Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116032 · ClinicalTrials.gov registry record
Immune Profiling for Cancer Immunotherapy Response
A clinical trial of Cancer and Hematologic Malignancy, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT06116032: Recruiting study of Cancer and Hematologic Malignancy, sponsored by Dartmouth-Hitchcock Medical Center.
NCT06116032 is a study of Cancer and Hematologic Malignancy that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 1,500 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06116032, a study of Cancer and Hematologic Malignancy, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Primary Outcome
The investigators will employ iRECIST, and outcome criteria will be clinically evaluated and include the primary endpoints of progression (non-responders) or response, with patients followed up every month for 6 months (or until death, loss to follow-up, or withdrawal of consent), judged according to the objective response rate (ORR) assessed using iRECIST.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Methylation Cytometry
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2029-01-01 |
What NCT06116032 shows while recruiting
NCT06116032 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Methylation Cytometry is the first listed.
NCT06116032 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06116032 about?
NCT06116032 is a clinical study titled "Immune Profiling for Cancer Immunotherapy Response". In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
What is the current status of trial NCT06116032?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2022-10-03. Estimated completion is 2029-01-01.
What conditions does trial NCT06116032 study?
This clinical trial studies the following conditions: Cancer, Hematologic Malignancy, Blood Cancer, Tumor, Solid.
What interventions are being tested in trial NCT06116032?
The interventions under investigation include: Methylation Cytometry (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06116032?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116032 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06116032's enrollment target sits among peer trials
1,500 68th of 615 higher than 545 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI